GlobeNewswire by notified

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Share

Company announcement – No. 56/ 2022

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, Denmark and Boston, MA, U.S. December 2, 2022 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached file(s).

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly.

Contact:

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nøkkelinformasjon ved kontantutbytte for Aurskog Sparebank8.2.2023 08:23:20 CET | Pressemelding

Utbyttebeløp: NOK 10,00 Annonsert valuta: NOK Siste dag inklusive: 08.03.23 Ex dato: 09.03.23 Record date (eierregisterdato): 10.03.23 Betalingsdato: 22.03.23 Vedtaksdato: 08.03.23 Informasjonen samsvarer med foreslått disponering i offentliggjort delårsrapport pr 31.12.22. Årsrapporten sluttbehandles av styret 01.03.23 og representantskapet behandler årsregnskap og disponering 08.03.23. Denne informasjonen offentliggjøres i henhold til kravene i Løpende forpliktelser.

Upgraded outlook for 20238.2.2023 08:09:58 CET | Press release

Jyske Bank expects earnings per share of DKK 60-70, corresponding to a net profit of DKK 4.0bn - 4.6bn and a profit before tax of DKK 5.3bn - 6.1bn in 2023. The intervals include one-off costs related to the integration of Handelsbanken Denmark, which are expected to amount to c. DKK 0.3bn. The outlook reflects the effects of the acquisition of Handelsbanken Denmark, the higher level of interest rates as well as a continued solid credit quality. The integration of the former Handelsbanken Denmark is progressing according to plan, both financially, commercially and organizationally. Previously, Jyske Bank expected earnings per share of DKK 55-65, corresponding to a net profit of DKK 3.7bn - 4.3bn in 2023. Yours faithfully, Jyske Bank Contact person: Birger Krøgh Nielsen, CFO, tel. +45 89 89 64 44. Attachment Corporate Announcement_20230208

Opjustering af forventet resultat i 20238.2.2023 08:09:58 CET | pressemeddelelse

Jyske Bank forventer et resultat pr. aktie på 60-70 kr., svarende til et resultat efter skat på 4,0-4,6 mia. kr. i 2023. Resultatintervallet før skat er 5,3-6,1 mia. kr. Forventningerne er inklusive integrations- og restruktureringsomkostninger i forbindelse med købet af Handelsbanken Danmark på ca. 0,3 mia. kr. Forventningerne afspejler helårseffekten af købet af Handelsbanken Danmark, det højere renteniveau og en fortsat solid kreditkvalitet. Sammenlægningen med det tidligere Handelsbanken Danmark forløber planmæssigt såvel økonomisk, forretningsmæssigt som organisatorisk. Tidligere var forventningerne et resultat pr. aktie på 55-65 kr., svarende til et resultat efter skat på 3,7-4,3 mia. kr. i 2023. Venlig hilsen Jyske Bank Kontaktperson: Birger Krøgh Nielsen, CFO, tlf. +45 89 89 64 44. Vedhæftet fil Selskabsmeddelelse_20230208

Key information related to proposed cash dividend to be paid by Yara International ASA8.2.2023 08:03:28 CET | Press release

Oslo, 8 February2023: The Board of Directors of Yara International ASA has decided to propose to the Annual General Meeting an ordinary dividend for 2022 of NOK 55 per share. The following are the key dates if the dividend is approved by the Annual General Meeting: Ex dividend NOK 55 as of: 13 June 2023 Record date: 14 June 2023 Dividend payment date: 22 June 2023 ADR dividend payment date: 29 June 2023 Date of approval: 12 June 2023 Contact Anika Jovik Head of Investor Relations Mobile: (+47) 472 24 959 E-mail: anika.jovik@yara.com About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger and a planet respected, we pursue a strategy of sustainable value growth, promoting climate-friendly crop nutrition and zero-emission energy solutions. Yara’s ambition is focused on growing a nature positive food future that creates value for our customers, shareholders and society at large and delivers a more sustainable foo

OP Gruppens bokslutskommuniké 1.1–31.12.2022: Resultatet före skatt var 1 265 miljoner euro – intäkterna ökade med 2 procent och kostnaderna låg på samma nivå som året innan8.2.2023 08:00:00 CET | Pressemelding

OP Gruppen Bokslutskommuniké 1.1–31.12.2022 Börsmeddelande 8.2.2023 kl. 9.00 OP Gruppens bokslutskommuniké 1.1–31.12.2022: Resultatet före skatt var 1 265 miljoner euro – intäkterna ökade med 2 procent och kostnaderna låg på samma nivå som året innan Resultatet före skatt var 1 265 miljoner euro (1 127).Intäkterna från kundrörelsen ökade med totalt 10 % till 3 512 miljoner euro (3 186). Räntenettot ökade med 15 % till 1 618 miljoner euro (1 409) och försäkringsnettot med 20 % till 889 miljoner euro (743). Provisionsnettot minskade med 3 % till 1 005 miljoner euro (1 034). Nettointäkterna från placeringsverksamheten minskade till -149 miljoner euro (376). Det tillfälliga undantaget ökade intäkterna från placeringsverksamheten med 143 miljoner euro (-118). Med beaktande av det tillfälliga undantaget minskade intäkterna från placeringsverksamheten totalt till -5 miljoner euro (257).Totalt minskade intäkterna med 5 % till 3 426 miljoner euro (3 616). Med beaktande av det tillfälliga undant